Cancer biotech Harpoon Therapeutics prices $76 million IPO at $14 midpoint

Shutterstock photo

Harpoon Therapeutics, a Phase 1 biotech developing T cell immunotherapies for various cancers, raised $76 million by offering 5.4 million shares at $14, the midpoint of the  $13 to $15 range. Harpoon Therapeutics plans to list on the Nasdaq under the symbol HARP. Citi and SVB Leerink acted as lead managers on the deal.

The article Cancer biotech Harpoon Therapeutics prices $76 million IPO at $14 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?